Aegerion Pharmaceuticals (AEGR) Clinical Update on Its Lomitapide

Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera. Aegerion Pharmaceuticals Incorporated - AEGR - provided a clinical update on its lomitapide. Aegerion reported that the 78-week data from its pivotal Phase III clinical trial is consistent with data previously reported at the 26- and 56-week time points.

http://www.nicovideo.jp/watch/sm16647975